Earnings: Perrigo 1st q. net profit plunges 27%

By YIGAL GRAYEFF
October 27, 2005 23:17
3 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

First-quarter net profit at pharmaceuticals company Perrigo plunged 27 percent but sales rose 40%, as the acquisition of Bnei Brak-based Agis Industries in March had a positive and negative effect on earnings.

In the three months ending on September 24, net profit fell to $12.9 million from $17.6m. in the same period a year earlier, earnings per share fell to 14 cents from 24 cents and revenue rose to $319.7m. from $227.7m., the company said Thursday.

Be the first to know - Join our Facebook page.


Analyst expectations for EPS ranged from 13 cents to 18 cents and for revenue they ranged from $317.7m. to $338.5m., as compiled by Thomson Financial Network.

The rise in sales reflected the addition of Agis's product sales, but net profit was hit by acquisition-related writeoffs of $3.7m. and charges of $3.3m. due to product recalls.

Despite the fall in net profit, US investors appeared to welcome the results and shares rose 4.6% to $13.45 in morning trading on Nasdaq despite only rising 0.2% to NIS 60.61 on the Tel Aviv Stock Exchange.



DSP Q3 net profit halves to $10.5m.



DSP Group's third-quarter net profit almost halved to $10.5m. from $20.4m. a year earlier, when it had a capital gain of $15.5m. following the sale of 1.65 million AudioCodes shares.

The semiconductor company said Thursday that excluding the gain, net profit for the three months ending on September 30 rose 7% from $9.8m. in the same period in 2004. Diluted earnings per share fell to 35 cents from 69 cents, including the gain, while revenue rose to $55.6m. from $46.2m., reflecting increased demand and market share in North America and a rise in shipments of to Japan.

Analyst expectations for earnings per share ranged from 31 cents to 35 cents and for revenue they ranged from $51m. and $55.5m., as compiled by Thomson Financial Network.

Shares fell 7% to $23.63 in morning trading on Nasdaq.



Zoran swings to Q3 net profit of $5m.

Haifa-based Zoran Corp. swung to a third-quarter net profit of $5m. from a net loss of $2.6m. a year earlier despite acquisition-related charges of $13.1m.

The company, which manufactures chips for consumer electronics products, said Thursday that in the three months ending September 30, earnings per diluted share were 11 cents compared with losses of 6 cents but that revenue slipped to $117.5m. from $119.7m.

Analyst expectations for EPS ranged from 13 cents to 16 cents and for revenue they ranged from $112m. to $117m., as compiled by Thomson Financial Network.

Zoran expects fourth-quarter losses per share of between 11 cents and 14 cents, due to acquisition-related costs of $13m., and revenue of between $104m. and $106m. Earlier this year the company bought Oren Semiconductor for $44.6m., increasing its stake from 17% to full ownership.

Investors cheered the return to profitability and shares had surged 14% to $14.74 by midday trading on Nasdaq.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS